In addition, trastuzumab treatment resulted in 39% reduced death rate, showing significantly improved overall survival benefit when early stage invasive HER2-positive breast cancer is treated with trastuzumab plus chemotherapy. The gene discussed is ERBB2; the disease is breast carcinoma.